Create Your Own Immortalized Cell Lines
Several methods exist for immortalizing mammalian cells in culture. Two of the most effective methods for achieving immortalization are transfecting primary cells with either the telomerase reverse transcriptase gene or viral genes. Viral genes, including Epstein-Barr virus (EBV), Simian virus 40 (SV40) T antigen, adenovirus E1A and E1B, and human papillomavirus (HPV) E6 and E7 induce immortalization by a process known as viral transformation. Although immortalization of cells by viral genes is reliable and relatively simple, these cells may become genetically unstable and lose the phenotypic properties of primary cells.
The preferred method to immortalize cells is through expression of the telomerase reverse transcriptase gene (TERT). The expression of TERT is repressed in most primary cells. When the catalytic component of TERT is transfected into cells, however, its expression leads to maintenance of the telomere end-regions of chromosomes. In most instances, this represses replicative senescence and induces the cells to become immortal. Analysis of many TERT-immortalized cell lines has verified that the cells maintain a stable genotype and retain critical phenotypic markers. In some instances, more than one immortalization agent may be required to successfully immortalize a particular cell type.
hTERT Cell Immortalization Product
pGRN145, plasmid in E. coli GC10, ATCC® MBA-141
Eukaryotic expression plasmid containing the hTERT reverse transcriptase cDNA.
The hTERT-containing plasmid is not available to commercial and for-profit organizations or for work to be conducted under funding from a commercial organization unless a commercial license is obtained. For information please e-mail ATCC's Office of IP, Licensing and Services.
Scientists at noncommercial and academic organizations who wish to use pGRN145 in their research need to download the Addendum for Noncommercial and Academic Organizations. These materials are subject to claims under U.S. Patent Nos. 6,261,836 and 6,337,200, other pending patent applications, and foreign counterparts thereof.
Epstein-Barr Viral Cell Transformation Product
B95-8, Epstein-Barr virus suspension, ATCC® VR-1492™
HPV E6/E7 Viral Transformation Products
PA317 LXSN16-E6E7, ATCC® CRL-2203™
PA317 LXSN16-E6, ATCC® CRL-2204™
PA317 LXSN16-E7, ATCC® CRL-2205™
These cell lines produce amphotropic retroviruses which encode either the HPV16 E6 (CRL-2204), the HPV E7 (CRL-2205), or both the HPV12 E6 and E7 open reading frames (CRL-2203), and which can be used to stably infect and immortalize many cell types.
pHPV-16 plasmid in E. coli, ATCC® 45113™
pHPV-16 purified plasmid DNA, ATCC® 45113D™
SV40 Viral Transformation Products
pUCSV40-B1E, ATCC® VRMC-2™
pUCSV40-B2E, ATCC® VRMC-3™
pUCSV40-CPC/MEN-1, ATCC® VRMC-4™
pUCSV40-VA45-54-1Ea, ATCC® VRMC-5™
pUCSV40-VA45-54-2Ea, ATCC® VRMC-6™
pUCSVH388-2, ATCC® VRMC-10™
pUCSVH388-16, ATCC® VRMC-11™
pUCSV40-2895-1, ATCC® VRMC-12™
pUCSV40-2895-2, ATCC® VRMC-13™
pUCSV40-T302-1, ATCC® VRMC-14™
pUCSV40-777-1, ATCC® VRMC-31™
pUCSV40-777-5, ATCC® VRMC-35™
SV40 Plasmids from Alliance for Cell Signaling
pEX_CFP6-SV40LTa_NLS plasmid in E. coli, ATCC® 10089303™
pEX_EF1_CFP6-SV40LTa_NLS plasmid in E. coli, ATCC® 10089305™
pEX_EF1_YFP6-SV40LTa_NLS plasmid in E. coli, ATCC® 10089307™
pEX_YFP6-SV40LTa_NLS plasmid in E. coli, ATCC® 10089309™
pEN_SV40LT_NLS, ATCC® 10373655™
These products are intended to be used for research purposes only. They are not to be used for drug or diagnostic purposes nor are they intended for human use. ATCC® products may not be resold, modified for resale, used to provide commercial services or to manufacture commercial products without ATCC's prior written agreement.
|